Qiming Venture Partners

Restricted Shares Will be Lifted on 22 September, and the Management and Investors of Arrail Group are "Hoarding", Release High Growth Signals

Retrieved on: 
Thursday, September 22, 2022
Cornerstone, Shanghai-Hong Kong Stock Connect, Policy, Qiming Venture Partners, City, Company, Hillhouse Capital Group, News, Goldman Sachs, Cognition, Industry, IPO, Hoarding, Temasek, Prospectus, Hospital, Health insurance, Security (finance)

HONG KONG, Sept 22, 2022 - (ACN Newswire) - The restricted shares of Arrail Group Limited ("Arrail Group" or the "Company", stock code: 06639.HK), a leading dental services group in China, will be officially lifted and listed for circulation on 22 September 2022.

Key Points: 
  • HONG KONG, Sept 22, 2022 - (ACN Newswire) - The restricted shares of Arrail Group Limited ("Arrail Group" or the "Company", stock code: 06639.HK), a leading dental services group in China, will be officially lifted and listed for circulation on 22 September 2022.
  • In this regard, the Company's management and investors clearly presented the idea of being "hoarding" and their current confidence.
  • Based on the confidence in the industry prospect and the future development of Arrail Group, the major investors of the Company said that they would continue to hold shares.
  • It is expected that the results and valuation of Arrail Group will be improved, thus promoting the further development of its dental services.

DeepWay completes ￥460 Million Series A financing

Retrieved on: 
Tuesday, August 23, 2022
CICC, China Construction Bank, Lenovo, Technology, Trust, Qiming Venture Partners, Research, Solution, TH, R, Terra Venture Partners, GLOBE, Capital, Series, Series A round, Industry, Transport, Rail transport

New York, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Recently, DeepWay, a smart electric commercial vehicle developer and manufacturer, announced it has completed 460 Million Series A financing, which was led by Qiming Venture Partners and backed by Lenovo Capital, Vlight Capital, CCB Trust, TH EDU Capital, Empowtech Capital, BOCOM International, and Huagai Capital.

Key Points: 
  • New York, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Recently, DeepWay, a smart electric commercial vehicle developer and manufacturer, announced it has completed 460 Million Series A financing, which was led by Qiming Venture Partners and backed by Lenovo Capital, Vlight Capital, CCB Trust, TH EDU Capital, Empowtech Capital, BOCOM International, and Huagai Capital.
  • CICC is the sole financial advisor for the Series A-Round financing.
  • DeepWay completes its first round of external financingwhich creates new record of the largest financing scale for smart electric commercial vehicle developing and manufacturing industry.
  • Congratulations for the successful completion of the Series A-Round financing of DeepWay team!

Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million

Retrieved on: 
Wednesday, August 10, 2022
Machine learning, Qiming Venture Partners, USP1, Warburg Pincus, Saudi Aramco, Fosun Pharma, Intelligence, Drug discovery, CEO, GLOBE, Venture round, Insilico Medicine, AI, Ecosystem, Technology, Robotics, Cancer, Agriculture, Medicine, Syngenta, Method, Pharma, Fibrosis, COVID-19, Company, Motion, Program, Peripheral nervous system, West Coast of the United States, Partnership, Biotechnology, CSO, Doctor of Philosophy, Biology, BHR Partners, Chemistry, In silico, Solution, Immunity, WS, Pharmaceutical industry, Medical device, Fine chemical

Insilicos founder and CEO, Alex Zhavoronkov, PhD, also invested in the Series D round.

Key Points: 
  • Insilicos founder and CEO, Alex Zhavoronkov, PhD, also invested in the Series D round.
  • Through a unique dual-CEO structure, Insilico Medicine is advancing its AI capabilities and drug research and development simultaneously.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.
  • Prosperity7 Ventures is the diversified growth fund of Aramco Ventures, a subsidiary of Aramco, the worlds leading integrated energy and chemicals company.

Berry Oncology launches HIFI Pan-Cancer Screening, a multi-cancer early screening product for detecting six high-risk cancers at one time

Retrieved on: 
Thursday, June 23, 2022
Qiming Venture Partners, Solution, Industry, Public health, Central committee, Overalls, Environment, Technology, Compliance, Hospital, Survival rate, WGS, Research, CEO, Survival, International Agency for Research on Cancer, Stomach, Recurrence, Liver cancer, HIFI, Pancreatic cancer, DNA, Nucleic acid thermodynamics, Colorectal cancer, Ecosystem, NGS, Quality of life, National Cancer Center, Esophageal cancer, Whole genome sequencing, University, State Council, Lung cancer, Patient, Organic, Communist party, Medicine, IARC, Diagnosis, Genetic testing, Awareness, Central China, Chinese Academy of Sciences, Chinese Academy of Medical Sciences COVID-19 vaccine, Goal, Mobile phone, Medical imaging, Cancer

HIFI Pan-Cancer Screening is the first early screening product for multiple cancer types using whole genome sequencing (WGS) of cell-free DNA (cfDNA) worldwide.

Key Points: 
  • HIFI Pan-Cancer Screening is the first early screening product for multiple cancer types using whole genome sequencing (WGS) of cell-free DNA (cfDNA) worldwide.
  • The self-iterative HIFI technology platform can reduce the costs of product development and testing services, and thus making early screening for multiple cancers more affordable.
  • The launch of the multi-cancer early screening product will further reinforce Berry Oncology's leadership in the early screening sector."
  • Moving forward, Berry Oncology will continue to optimize its technology system and iterate early screening products to deliver more advanced early cancer screening solutions in accordance with the actual market demand and environment.

BRV China-backed Js Design Secures Tens of Millions USD in Series B+ Financing

Retrieved on: 
Friday, June 17, 2022
Solution, Robotics, Industry, Waterdrop, Qiming Venture Partners, Culture, Conifer cone, Software as a service, RMB, UI, WDH, USD, PPTV, BRV, Venture round, NASDAQ, API, Preqin, Software, Transport, NYSE, Language, Video game, Silicon

BEIJING, June 17, 2022 /PRNewswire/ -- Js Design, a leading cloud-based UI design tool developer in China, has recently secured tens of millions USD in Series B+ financing. BlueRun Ventures China (BRV China) has co-led the company's Series A funding and has participated in the later A+ and B rounds.

Key Points: 
  • BEIJING, June 17, 2022 /PRNewswire/ --Js Design, a leading cloud-based UI design tool developer in China, has recently secured tens of millions USD in Series B+ financing.BlueRun Ventures China (BRV China) has co-led the company's Series A fundingand has participated in the later A+ and B rounds.
  • Founded in September 2020, Js Design is China's first professional cloud-based open-source UI design tool.
  • Js Design furthered its commercialization through close collaboration with a number of key industry players in China.
  • We are happy to see Js Design reaching a new milestone and winning recognition from more investors."

Boulder Care raises $36M Series B to serve America's most vulnerable patients with substance use disorders

Retrieved on: 
Friday, June 10, 2022
EAP, Qiming Venture Partners, LTM, First Round Capital, Research, Health equity, Income, Yoy, Empowerment, NIH, Patient satisfaction, Patient, West Midlands CARE Team, Hospital, Comcast, National Institute on Drug Abuse, Industry, U.S. Venture Partners, SUD, Joint, Hewlett-Packard, Medicaid, National Institute, Case management (US healthcare system), Joint Commission, Housing, Safety, Pharmaceutical industry, Health insurance, Régence

PORTLAND, Ore., June 10, 2022 /PRNewswire/ -- Boulder Care, a telehealth provider of medical treatment and long-term support for people overcoming substance use disorders, today announced a $36 million Series B raise.

Key Points: 
  • PORTLAND, Ore., June 10, 2022 /PRNewswire/ -- Boulder Care, a telehealth provider of medical treatment and long-term support for people overcoming substance use disorders, today announced a $36 million Series B raise.
  • "At Boulder, we envision a dramatically better safety net for the most underserved starting with SUD care delivered with humility and empowerment.
  • Linking arms with insurers has helped Boulder make care affordable for low-income Americans who are fighting hard to recover.
  • Boulder helps achieve better health outcomes, patient satisfaction, and long-term retention in care while reducing costs through innovative value-based payment arrangements.

Qiming Venture Partners USA Announces $260 Million US Healthcare Fund III and Addition of New Partner, Isaac Ciechanover

Retrieved on: 
Thursday, June 2, 2022
General Health, Professional Services, Health, Finance, FirstMark Capital, Epidemiology, Qiming Venture Partners, EfTEN Real Estate Fund III, PTC, Kleiner Perkins, Partner, Cornell University, Celgene, Weill Cornell Medicine, ATRA, Harvard University, Therapy, Patient, Polaris Partners, PTC Therapeutics, NASDAQ, University of Cambridge, XLRN, Stanford University, Byers, Cancer, Pharmaceutical industry, EU, Psychology

Qiming Venture Partners USA (Qiming US), a leading US healthcare investment firm, today announced the closing of its third fund, raising $260 million in an oversubscribed fundraise with strong support from new and existing investors.

Key Points: 
  • Qiming Venture Partners USA (Qiming US), a leading US healthcare investment firm, today announced the closing of its third fund, raising $260 million in an oversubscribed fundraise with strong support from new and existing investors.
  • In addition to closing Fund III, Qiming US announced the addition of Isaac Ciechanover, M.D., as a Partner.
  • Isaac Ciechanover joins Qiming US from Polaris Venture Partners where he served as a Partner.
  • Established in 2017, Qiming US is an independent, US-based venture capital firm affiliated with Qiming Venture Partners, one of the leading venture capital firms in China.

Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory

Retrieved on: 
Monday, June 6, 2022
Chemistry, Qiming Venture Partners, Fosun Pharma, West Coast of the United States, Fibrosis, Biology, Program, Warburg Pincus, Research, Doctor of Philosophy, BHR Partners, Artificial intelligence, AI, CEO, Immunity, Partnership, IND, Solution, Pharma, Intelligence, Peripheral nervous system, Machine learning, Growth, Robotics, Patient, Venture round, Medicine, Cros, COVID-19, Drug discovery, Insilico Medicine, USP1, Ageing, Cancer, Medical device, Pharmaceutical industry, In silico

They have demonstrated the value of combining deep scientific expertise with cutting-edge technology capabilities to significantly accelerate drug discovery.

Key Points: 
  • They have demonstrated the value of combining deep scientific expertise with cutting-edge technology capabilities to significantly accelerate drug discovery.
  • In 2022, Insilico signed a multi-asset partnership deal with Fosun Pharma in January, and a drug discovery co-development deal with EQRx in March.
  • Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.

Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory

Retrieved on: 
Monday, June 6, 2022
Chemistry, Qiming Venture Partners, Fosun Pharma, West Coast of the United States, Fibrosis, Biology, Program, Warburg Pincus, Research, Doctor of Philosophy, BHR Partners, Artificial intelligence, AI, CEO, Immunity, Partnership, IND, Solution, Pharma, Intelligence, Peripheral nervous system, Machine learning, Growth, Robotics, Patient, Venture round, Medicine, Cros, COVID-19, Drug discovery, Insilico Medicine, USP1, Ageing, Cancer, Medical device, Pharmaceutical industry, In silico

They have demonstrated the value of combining deep scientific expertise with cutting-edge technology capabilities to significantly accelerate drug discovery.

Key Points: 
  • They have demonstrated the value of combining deep scientific expertise with cutting-edge technology capabilities to significantly accelerate drug discovery.
  • In 2022, Insilico signed a multi-asset partnership deal with Fosun Pharma in January, and a drug discovery co-development deal with EQRx in March.
  • Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.

LanzaTech Appoints Dr. Steven F. Stanley, PhD as Chief Commercial Officer

Retrieved on: 
Monday, May 16, 2022
Carbon, Oil, Engineering, Plant, Aviation biofuel, Nasdaq, News, Biology, ArcelorMittal, BASF, CCO, Synthetic biology, Dow Chemical Company, Qiming Venture Partners, Artificial intelligence, New Zealand Superannuation Fund, Ethanol, Transformation, Lululemon Athletica, Virgin Atlantic, Primetals Technologies, Mitsui & Co., Technology, Machine learning, CO2, Khosla Ventures, LLC, Growth, CEO, Stanley, GLOBE, Renewable energy, Unilever

CHICAGO, May 16, 2022 (GLOBE NEWSWIRE) -- LanzaTech NZ, Inc. (LanzaTech), an innovative Carbon Capture and Transformation (CCT) company that transforms waste carbon into materials such as sustainable fuels, fabrics, packaging, and other products that people use in their daily lives, announces today that Steven F. Stanley, Ph.D., has joined LanzaTech as Chief Commercial Officer (CCO).

Key Points: 
  • CHICAGO, May 16, 2022 (GLOBE NEWSWIRE) -- LanzaTech NZ, Inc. (LanzaTech), an innovative Carbon Capture and Transformation (CCT) company that transforms waste carbon into materials such as sustainable fuels, fabrics, packaging, and other products that people use in their daily lives, announces today that Steven F. Stanley, Ph.D., has joined LanzaTech as Chief Commercial Officer (CCO).
  • I am proud of the growth of our company and the vital role our technology is playing in creating a post pollution future, said Dr. Jennifer Holmgren, CEO of LanzaTech.
  • Having Steven on board as our Chief Commercial Officer will help us reach new clients worldwide by changing the way they think about waste carbon, treating it as an opportunity instead of a liability.
  • As previously announced LanzaTech has entered into a merger agreement for a business combination transaction with AMCI Acquisition Corp. II (Nasdaq: AMCI).